These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 28288138)

  • 1. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
    Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
    Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
    Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
    Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
    PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
    Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Kim EY; Kim A; Kim SK; Chang YS
    Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
    Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Vendetti F; Vancriekinge W; Demeyer T; Du Z; Parsana P; Rodgers K; Yen RW; Zahnow CA; Taube JM; Brahmer JR; Tykodi SS; Easton K; Carvajal RD; Jones PA; Laird PW; Weisenberger DJ; Tsai S; Juergens RA; Topalian SL; Rudin CM; Brock MV; Pardoll D; Baylin SB
    Oncotarget; 2013 Nov; 4(11):2067-79. PubMed ID: 24162015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphine-3-glucuronide upregulates PD-L1 expression
    Wang K; Wang J; Liu T; Yu W; Dong N; Zhang C; Xia W; Wei F; Yang L; Ren X
    Cancer Biol Med; 2021 Feb; 18(1):155-171. PubMed ID: 33628591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Jeong H; Koh J; Kim S; Song SG; Lee SH; Jeon Y; Lee CH; Keam B; Lee SH; Chung DH; Jeon YK
    Br J Cancer; 2024 Jul; 131(1):23-36. PubMed ID: 38729997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.